Edition:
United States

Verastem Inc (VSTM.OQ)

VSTM.OQ on NASDAQ Stock Exchange Global Market

2.32USD
23 Jun 2017
Change (% chg)

-- (--)
Prev Close
$2.32
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
71,061
52-wk High
$2.53
52-wk Low
$1.07

VSTM.OQ

Chart for VSTM.OQ

About

Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's... (more)

Overall

Beta: 2.14
Market Cap(Mil.): $85.82
Shares Outstanding(Mil.): 36.99
Dividend: --
Yield (%): --

Financials

  VSTM.OQ Industry Sector
P/E (TTM): -- 239.63 19.01
EPS (TTM): -1.11 -- --
ROI: -51.61 -8.17 -5.03
ROE: -52.61 -11.48 -4.28

BRIEF-Verastem director Barberich buys 30,000 shares of co's common stock on May 15

* Verastem Inc director Timothy Barberich reports purchase of 30,000 shares of co's common stock on May 15 at average price of $2.45 per share - SEC filing Source text: (http://bit.ly/2pKDBMW) Further company coverage:

May 17 2017

BRIEF-Verastem Q1 loss per share $0.35

* Q1 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

May 10 2017

BRIEF-Verastem reports year-end 2016 financial results

* Expect to have sufficient cash, cash equivalents and investments to fund our research and development programs and operations into 2018

Mar 23 2017

BRIEF-Verastem announces dosing of first patient in Defactinib and Avelumab trial

* Verastem announces dosing of first patient in combination trial of Defactinib and Avelumab in patients with ovarian cancer

Jan 26 2017

More From Around the Web

Earnings vs. Estimates